For research use only. Not for therapeutic Use.
Tigloidin is an analogue of atropine, with anticholinergic activity.
Tigloidine hydrobromide (20-60 mg/kg, i.p.) fails to protect the mice against the lethal effect of physostigmine, but at 100 mg/kg and above, it protects 80% of the animals against the lethal effect. Tigloidine markedly prevents tremor and salivation produced by tremorine at 80-100 mg/kg, but fails to prevent these effects in doses up to 40 mg/kg. Tigloidine (up to 100 mg/kg, i.p) does not significantly affects reserpine and tetrabenazine induced sedation and ptosis in mice. Tigloidine (25-50 mg/kg, i.p.) also fails to cause any behavioral changes in the cats[1].
| Catalog Number | I013462 |
| CAS Number | 495-83-0 |
| Synonyms | [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (E)-2-methylbut-2-enoate |
| Molecular Formula | C13H21NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H21NO2/c1-4-9(2)13(15)16-12-7-10-5-6-11(8-12)14(10)3/h4,10-12H,5-8H2,1-3H3/b9-4+/t10-,11+,12? |
| InChIKey | UVHGSMZRSVGWDJ-ZCFDAEMWSA-N |
| SMILES | CC=C(C)C(=O)OC1CC2CCC(C1)N2C |
| Reference | [1]. Sanghvi I, et al. Pharmacology of a potential anti-Parkinson agent: tigloidine. Eur J Pharmacol. 1968 Oct;4(3):246-53. |
